Navigation Links
Particle Sciences Expands Biopharmaceutical Development Infrastructure
Date:7/15/2014

BETHLEHEM, Pa., July 15, 2014 /PRNewswire/ -- Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis.  According to Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property.  We regularly work with biopharmaceuticals and vaccines ranging from therapeutic proteins, including monoclonal antibodies, to nucleotides, to vaccine antigens and immunomodulators.  Adding cell culture and extensive instrumentation to support the testing and characterizations of these biopharmaceuticals was planned for later this year but we've accelerated implementation to meet our client's needs."   With this most recent expansion, Particle Sciences can now run the full gambit of testing including, among others, ELISA, SDS-PAGE, Western blots, image analysis, HPLC, HPLC-MS, ligand-receptor binding assays, cellular proliferation, cytotoxicity and cellular activation assays.   

Mark Mitchnick, Particle Sciences' CEO added, "This expansion augments our existing formulation and sterile manufacturing offerings.  With our unique approach to biopharmaceutical formulation and the ability to quickly take our clients into the clinic, Particle Sciences anticipates becoming a leader in large molecule formulation and clinical trial supply."  The company sees a rapidly growing industrial need for these services as biopharmaceutical and biosimilar products become an increasingly important component to the health care products market. Particle Sciences' formulation portfolio enables the broader, more efficient development and application of biopharmaceuticals, and can differentiate products in the biosimilars field.

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  We also have an extensive history in government contracting alongside our clients.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com,  email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Contact: Maureen Grieco
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shimadzu Introduces New Particle Size Analyzer for Measurement of Nanoparticles in Life Sciences and R&D
2. New magnetic behavior in nanoparticles could lead to even smaller digital memories
3. DNA motor walks along nanotube, transports tiny particle
4. Nanoparticles and their orbital positions
5. Researchers split water into hydrogen, oxygen using light, nanoparticles
6. IceCube Particle Detector in Antarctica Records High-energy Neutrinos
7. Scientists develop way to successfully give nanoparticle therapeutics orally
8. Pills of the future: Nanoparticles
9. Ultra-sensitive force sensing with a levitating nanoparticle
10. Magnetic nanoparticles could aid heat dissipation
11. BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection ... American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El ...
(Date:2/10/2016)... -- NX Prenatal Inc., a US based molecular ... early warning of adverse pregnancy outcomes, announced today ... Dr. Thomas McElrath of Brigham & ... (SMFM) annual meeting held in Atlanta ... presentation reported initial positive top-line results regarding the ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., a ... fast growing biotech companies, announced today the appointment ... Strategic Advisor. Jim brings nearly 25 years of ... procurement, having spent nearly two decades in executive ... and Procurement at Genzyme and, most recently headed ...
(Date:2/10/2016)... ... 10, 2016 , ... PatientCrossroads announces that the ... online PatientCrossroads platform, has exceeded both its one-year and overall recruitment goals since ... which seeks to advance understanding of the hereditary risks for certain kinds of ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
Breaking Biology News(10 mins):